Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra®) in the US and Canada: Retrospective Study of Patient Characteristics, Treatment Patterns, and Clinical Effectiveness in 600 Patients with Dry Eye Disease
John A Hovanesian,Kelly K Nichols,Mitchell Jackson,James Katz,Arthur Chan,Mrudula B Glassberg,Brigitte Sloesen,Caroline Korves,Catherine Nguyen,Annie Syntosi
DOI: https://doi.org/10.2147/OPTH.S296510
2021-03-08
Clinical Ophthalmology
Abstract:John A Hovanesian, 1, 2 Kelly K Nichols, 3 Mitchell Jackson, 4 James Katz, 5 Arthur Chan, 6 Mrudula B Glassberg, 6 Brigitte Sloesen, 7 Caroline Korves, 8 Catherine Nguyen, 9 Annie Syntosi 7 1 Harvard Eye Associates, Laguna Hills, CA, USA; 2 UCLA Jules Stein Eye Institute, Los Angeles, CA, USA; 3 School of Optometry, University of Alabama at Birmingham, Birmingham, AL, USA; 4 Jacksoneye, Lake Villa, IL, USA; 5 The Midwest Center for Sight, Des Plaines, IL, USA; 6 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 7 Novartis Pharma AG, Basel, Switzerland; 8 Analysis Group, Inc., Boston, MA, USA; 9 Analysis Group, Inc., Los Angeles, CA, USA Correspondence: Annie Syntosi Retina Global Patient Access, Novartis Campus, Lichtstrasse 35, Basel, 4056, Switzerland Tel +41 763785855 Email annie.syntosi@novartis.com Purpose: This study evaluated real-world treatment of dry eye disease (DED) with lifitegrast. Patients and Methods: Ophthalmologists and optometrists treating patients with DED were invited to participate through a healthcare provider (HCP)-based panel. HCPs completed a provider survey and contributed data toward a chart review for up to five qualifying patients with DED who initiated lifitegrast ophthalmic solution (index date) between 01/01/2017 (US) or 01/01/2018 (Canada) and 06/30/2019. Patient demographics, treatments, clinical characteristics, and outcomes (ie, severity, signs, symptoms) were collected for the 6-month pre-index period and up to 12-months post-index. Results: For this study, 517 HCPs contributed 600 patient charts. Among 554 and 281 patients with follow-up at 6 and 12-months post-index, 512 (92.4%) and 238 (84.7%) patients had ongoing lifitegrast treatment, respectively. Other DED-related treatments were less frequently used post-index with lifitegrast vs pre-index: over-the-counter artificial tear use (45.2% vs 75.5%), topical corticosteroids (3.8% vs 18.8%), any cyclosporine (3.0% vs 20.5%). At 3-months (n=571) and 12-months (n=320) post-index vs pre-index, fewer patients had eye dryness (47 [8.2%] and 16 [5.0%] vs 525 [87.5%]), blurred vision (28 [4.9%] and 11 [3.4%] vs 346 [57.7%]), ocular burning/stinging (25 [4.4%] and 8 [2.5%] vs 336 [56.0%]), depression (8 [1.4%] and 9 [2.8%] vs 55 [9.2%]), fatigue (4 [0.7%] and 1 [0.3%] vs 82 [13.7%]), and headache (1 [0.2%] and 0 vs 19 [3.2%]). At 3 and 12-months post-index vs pre-index, average corneal staining score was numerically lower (2.7 and 2.0 vs 6.5), and average Schirmer score (10.6 and 10 vs 6.3) and tear film break-up time (7.3 and 8.0 vs 4.8) higher. Conclusion: The majority of patients had ongoing lifitegrast treatment 6-months post-index with reduction in overall treatment burden. Improvement in DED signs and symptoms, including QoL impacts, was evident at 3 months and up to 12 months after lifitegrast initiation. Keywords: symptoms, signs, severity, QoL